Actively Recruiting
Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery
Led by Tongji Hospital · Updated on 2025-06-17
166
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to access the safety of etomidate - propofol mixture vs propofol for total intravenous anesthesia in elderly patients undergoing abdominal surgery.
CONDITIONS
Official Title
Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ASA Ⅰ~Ⅲ;
- BMI was 18-28 kg/m2;
- For elective abdominal surgery under intravenous general anesthesia;
- The expected duration of anesthesia was 1 to 4 hours.
You will not qualify if you...
- Septic shock and multiple organ failure diagnosed within 14 days;
- Hyperkalemia (serum potassium >5.5mmol/L) within 48 hours;
- Stroke or transient ischemic attack within 3 months;
- Patients with unstable angina pectoris or myocardial infarction within 3 months; Arrhythmia requiring treatment was not treated or treatment did not meet expectations;
- Patients with preoperative diagnosed diabetes mellitus and uncontrolled blood glucose; Diabetic complications were diagnosed before surgery, including diabetic ketoacidosis, hyperosmolar coma, diabetes-related infection, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc.
- Severe liver and renal dysfunction;
- Liver surgery, renal surgery, adrenal surgery, day surgery;
- Resting blood pressure ≥180/110 mmHg (2020 ISH hypertension guideline ≥ grade 3 hypertension); Or systolic blood pressure <90mmHg or mean blood pressure <65mmHg.
- Taking corticosteroids or other immunosuppressants for more than 10 days within 6 months or having a history of adrenal cortex suppression or immune system diseases;
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
S
Shiyong Li
CONTACT
Q
Qiang Han, 02783665480
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here